A fenbendazole methyl-β-cyclodextrin inclusion compound and preparation method thereof

By forming an inclusion compound with methyl-β-cyclodextrin, the problems of low water solubility and bioavailability of fenbendazole are solved, and its solubility and bioavailability are significantly improved, making it less The same therapeutic effect was achieved at doses.

CN118340910BActive Publication Date: 2024-12-06WENZHOU-KEAN UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410401056.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-03
Publication Date
2024-12-06
Estimated Expiration
2044-04-03

AI Technical Summary

Technical Problem

The low water solubility and low bioavailability of fenbendazole limit its application in clinical practice, and the prior art is difficult to improve its solubility to meet the requirements of cancer treatment dose.

Method used

By forming an inclusion with methyl-β-cyclodextrin, using specific stirring reaction conditions and solvents, the solubility of fenbendazole is increased to 20.21 mg/mL, significantly improving its bioavailability.

Benefits of technology

The solubility of fenbendazole methyl-β-cyclodextrin inclusions was increased by 60,000 times, and the bioavailability of fenbendazole and its metabolites was increased to 138%, 149% and 169%, respectively, at a smaller dose To achieve the same therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118340910B_ABST
    Figure CN118340910B_ABST
Patent Text Reader

Abstract

The present invention provides a fenbendazole methyl β-cyclodextrin inclusion compound and a preparation method thereof, wherein the ingredients include methyl β-cyclodextrin and fenbendazole. The preparation method of the inclusion compound comprises the following steps: mixing a methyl β-cyclodextrin solution with a fenbendazole solution, stirring the reaction, removing the solvent, and purifying to obtain a product. The present invention reacts fenbendazole with methyl β-cyclodextrin, and the solubility is increased to 20.21 mg / mL, which is 60,000 times higher than the effect of fenbendazole alone; in an in vivo pharmacokinetic study, the release amount of fenbendazole within 15 minutes is 75%, and the bioavailability of fenbendazole and its main metabolic anthelmintic oxfendazole and the secondary metabolic anthelmintic oxfendazole is increased to 138%, 149% and 169% respectively, so that it can achieve the same therapeutic effect at a lower dose, and the inclusion compound can be used as a potential anticancer drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medicines, and mainly relates to a fenbendazole methyl-beta-cyclodextrin inclusion compound and a preparation method thereof. Background Art

[0002] Fenbendazole is an orally effective benzimidazole anthelmintic with the characteristics of broad antiparasitic activity, high efficiency and low toxicity. It is widely used in agriculture and animal husbandry to control parasites. More importantly, as a microtubule destabilizing agent, fenbendazole's effect on helminths is mainly through binding to tubulin and disrupting the tubulin-microtubule balance, stabilizing the transcription activator HIF-1α, leading to cell cycle arrest and mitotic cell death. It is not only widely used in agriculture and animal husbandry to control parasites, but also shows anticancer effects on several types of cancer, and also has anticancer effects on paclitaxel and doxorubicin-resistant cancer cells. However, fenbendazole has poor water solubility (0.3μg / mL), which limits its clinical application. Even though great efforts have been made to improve its water solubility, the effect is not significant. According to the FDA's biopharmaceutical classification, albendazole belongs to the low permeability, low solubility IV class of drugs. Anticancer drugs administered by IP or IV routes usually require a water solubility of 5-10mg / mL because low concentrations of fenbendazole require a large volume to achieve the required therapeutic dose. Low water solubility and low bioavailability limit the clinical application of fenbendazole. Improving its solubility can effectively improve its medical application.

[0003] In existing studies, cyclodextrin is usually used to form inclusion complexes with fenbendazole to change its physical and chemical properties and improve its wettability, solubility and stability. Through the aqueous solution method, fenbendazole is complexed with HP-β-cyclodextrin or β-cyclodextrin, and the solubility of fenbendazole in β-cyclodextrin (4% w / v) solution is 40μg / mL, and the solubility in HP-β-cyclodextrin (10% w / v) solution is 100μg / mL; under the same conditions, the complex with β-cyclodextrin can increase the water solubility of fenbendazole from 0.1054μg / mL to 45.56μg / mL, and the complex with HP-β-cyclodextrin can increase the water solubility of fenbendazole to 159.36μg / mL.

[0004] In addition to cyclodextrin complexation, many other strategies have been used in existing studies to improve the aqueous solubility of fenbendazole.

[0005] Preparation of fenbendazole mesylate and mesylate salts can improve the water solubility of fenbendazole, preparation of supramolecular complexes of fenbendazole with polyvinylpyrrolidone polymer can increase the solubility of fenbendazole by 2.8 times, and self-dispersible nanocrystals prepared with fenbendazole and poloxamer 188 in a 1:1 ratio were used for in vivo PK studies of fenbendazole. Fenbendazole containing the Mobil composition of substance 41 has enhanced delivery capacity to PC-3 cells, micelles containing fenbendazole and rapamycin (1:2 ratio) prepared by freeze drying method have slow release in vitro, fenbendazole encapsulated poly (D, l-lactic-co-glycolic acid) acid nanoparticles prepared by oil-in-water emulsion method can improve water solubility, enhance absorption, and exert significant anticancer effects in EOC cells and xenograft models including PDX, fenbendazole was dispersed in PEO / PCL blend matrix prepared by hot melt extrusion, and the results showed that the rate of PCL delaying drug release was proportional to the content of this polymer incorporated. Other studies have evaluated the compatibility of fenbendazole with three polymer excipients, and polyethylene oxide / polycaprolactone plasticized solid dispersions and fenbendazole tablets improved the solubility and release of the drug.

[0006] However, these studies did not significantly improve the solubility and could not meet the required cancer treatment dose (5-10 mg / mL).

[0007] Therefore, more research is needed to find new formulations of fenbendazole with significantly improved solubility and to evaluate its structure, solubility, pharmacokinetics and other properties. Summary of the invention

[0008] The invention provides a fenbendazole methyl-β-cyclodextrin inclusion complex, the solubility of fenbendazole is increased to 20.21 mg / mL, which is the best effect so far, 60,000 times higher than the effect of single inclusion fenbendazole, and the bioavailability is also greatly improved, and the same therapeutic effect can be achieved at a lower dose.

[0009] An object of the present invention is to provide a fenbendazole methyl-β-cyclodextrin inclusion compound, wherein the fenbendazole methyl-β-cyclodextrin inclusion compound comprises the following components: methyl-β-cyclodextrin and fenbendazole.

[0010] Furthermore, the mass ratio of the methyl-β-cyclodextrin to fenbendazole is (1-3):1.

[0011] Another object of the present invention is to provide a method for preparing the above-mentioned fenbendazole methyl-β-cyclodextrin inclusion compound, the method for preparing the fenbendazole methyl-β-cyclodextrin inclusion compound comprising the following steps:

[0012] The methyl-β-cyclodextrin solution and the fenbendazole solution are mixed, stirred for reaction, and then the solvent is removed and the product is obtained after purification.

[0013] Furthermore, the solvent of the fenbendazole solution is an organic acid.

[0014] Furthermore, the organic acid is selected from one or more of formic acid and acetic acid.

[0015] Furthermore, the stirring reaction temperature is 20-60°C.

[0016] Furthermore, the rotation speed of the stirring reaction is 300-550r / min.

[0017] Furthermore, the stirring reaction time is 2-5h.

[0018] The present invention has the following beneficial effects:

[0019] The fenbendazole methyl-β-cyclodextrin inclusion compound provided by the present invention is formed by the reaction of fenbendazole and methyl-β-cyclodextrin, and the solubility is increased to 20.21 mg / mL, which is the best effect so far, and is 60,000 times higher than the effect of single inclusion of fenbendazole. In addition, in the in vivo pharmacokinetic study, the release amount of fenbendazole within 15 minutes is 75%, and the bioavailability of fenbendazole and its main metabolic anthelmintic oxfendazole and the secondary metabolic anthelmintic oxfendazole are respectively increased to 138%, 149% and 169%, so that the same therapeutic effect can be achieved at a lower dose, indicating that the inclusion compound can be used as a potential anticancer drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The structures of fenbendazole and fenbendazole methyl-β-cyclodextrin inclusion complex are shown;

[0021] in,

[0022] Figure 1 (a) is the structure of fenbendazole;

[0023] Figure 1 (b) is the structure of fenbendazole methyl-β-cyclodextrin inclusion complex.

[0024] Figure 2 The differential scanning calorimetry scanning results of methyl-β-cyclodextrin, fenbendazole, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1, and the physical mixture prepared in the comparative example are shown.

[0025] Figure 3 The scanning electron microscope images of methyl-β-cyclodextrin, fenbendazole, fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 and physical mixture prepared in Comparative Example are shown;

[0026] in,

[0027] Figure 3 (a) is a scanning electron microscope image of methyl-β-cyclodextrin;

[0028] Figure 3 (b) is a scanning electron microscope image of fenbendazole;

[0029] Figure 3 (c) is a scanning electron microscope image of fenbendazole methyl-β-cyclodextrin inclusion complex;

[0030] Figure 3 (d) is the scanning electron microscope image of the physical mixture of fenbendazole and methyl-β-cyclodextrin.

[0031] Figure 4 The nuclear magnetic resonance spectra of methyl-β-cyclodextrin, fenbendazole, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 and the physical mixture prepared in the comparative example are shown;

[0032] in,

[0033] Figure 4 (a) is methyl-β-cyclodextrin in D 2 Proton NMR spectrum in O;

[0034] Figure 4 (b) is the inclusion complex of fenbendazole methyl-β-cyclodextrin in D 2 Proton NMR spectrum in O;

[0035] Figure 4 (c) Fenbendazole methyl-β-cyclodextrin inclusion complex in D 2 Roesy spectrum in O.

[0036] Figure 5 The dissolution rates of fenbendazole, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1, and the physical mixture prepared in the comparative example are shown.

[0037] Figure 6 The HPLC standard curve of fenbendazole established based on peak area and concentration is shown.

[0038] Figure 7 The solubility of fenbendazole in aqueous solutions of β-cyclodextrin at different concentrations is shown.

[0039] Figure 8 Standard curves and regression equations for fenbendazole, oxibendazole, and fenbendazole sulfone in plasma are shown;

[0040] in,

[0041] Figure 8 (a) fenbendazole;

[0042] Figure 8 (b) is oxabendazole;

[0043] Figure 8 (c) is fenbendazole sulfone.

[0044] Fig. 9 shows the concentration-time curves of fenbendazole, oxfendazole and fenbendazole sulfone in the plasma of dogs administered fenbendazole or its methyl-β-cyclodextrin inclusion complex, as determined by HPLC;

[0045] in,

[0046] Fig. 9 (a) fenbendazole;

[0047] Fig. 9 (b) is oxabendazole;

[0048] Fig. 9 (c) is fenbendazole sulfone. DETAILED DESCRIPTION

[0049] In order to more clearly illustrate the technical solution of the present invention, the following examples are listed. Unless otherwise stated, the raw materials, reactions and post-treatment methods shown in the examples are common raw materials on the market and technical methods well known to those skilled in the art.

[0050] The words "preferred", "preferably", "more preferably", etc. in the present invention refer to embodiments of the present invention that can provide certain beneficial effects in certain circumstances. However, other embodiments may also be preferred under the same circumstances or other circumstances. In addition, the description of one or more preferred embodiments does not imply that other embodiments are not applicable, nor is it intended to exclude other embodiments from the scope of the present invention.

[0051] It should be understood that, except in any operating examples, or where otherwise indicated, all numbers indicating, for example, the amounts of ingredients used in the specification and claims should be understood to be modified in all cases by the term "about". Therefore, unless indicated to the contrary, the numerical parameters set forth in the following specification and the appended claims are approximate values ​​that vary depending on the desired properties to be obtained by the present invention.

[0052] In the examples and comparative examples, the following materials were used:

[0053] Fenbendazole with a purity of 99.9% and a fenbendazole content of 98% was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. (Shanghai, China).

[0054] β-cyclodextrin, HP-β-cyclodextrin, methyl-β-cyclodextrin (average molecular weight: 1303), γ-cyclodextrin and HP-γ-cyclodextrin aqueous solution were purchased from Shanghai MacLean.

[0055] The experimental dogs were purchased from Guangdong Medical Experimental Animal Center.

[0056] Blank canine plasma was purchased from Guangzhou Ruite Biotechnology Co., Ltd. (Guangzhou, Guangdong, China).

[0057] Low-fat dog food was purchased from Shanghai Jibai Chong Industrial Co., Ltd. (Shanghai, China).

[0058] Unless otherwise stated, the water in the embodiments of the present invention is ultrapure water.

[0059] In the test examples of the present invention, the statistical analysis method is: each experiment is repeated three times, and the test results are expressed in the form of "mean ± standard deviation (mean ± SD)". Graphpad Prism 9 software is used to draw graphs and perform statistical analysis on the data. P ≤ 0.05 is considered to be statistically significant.

[0060] Example 1

[0061] A fenbendazole methyl-β-cyclodextrin inclusion compound, the preparation method of which comprises the following steps:

[0062] A 29.9 mg / mL fenbendazole formic acid solution and a 140 mg / mL methyl-β-cyclodextrin aqueous solution were mixed at a ratio of fenbendazole:methyl-β-cyclodextrin=1:1 (m / m), and stirred at 500 r / min for 3 hours at a temperature of 50°C. The resulting solution was stored in a refrigerator at 4°C for 8 hours, the solvent was removed by rotary evaporation, the residue was dissolved in water, filtered with a 22 μm filter membrane, and freeze-dried under reduced pressure to obtain the fenbendazole methyl-β-cyclodextrin inclusion complex.

[0063] Figure 1 The structures of fenbendazole and fenbendazole methyl-β-cyclodextrin inclusion complex are shown;

[0064] in,

[0065] Figure 1 (a) is the structure of fenbendazole;

[0066] Figure 1 (b) is the structure of fenbendazole methyl-β-cyclodextrin inclusion complex.

[0067] Example 2

[0068] A fenbendazole methyl-β-cyclodextrin inclusion compound, the preparation method of which comprises the following steps:

[0069] A 29.9 mg / mL fenbendazole formic acid solution and a 140 mg / mL methyl-β-cyclodextrin aqueous solution were mixed at a ratio of fenbendazole:methyl-β-cyclodextrin=1:1.5 (m / m), and stirred at 500 r / min for 4 hours at a temperature of 55°C. The resulting solution was stored in a refrigerator at 4°C for 10 hours, the solvent was removed by rotary evaporation, the residue was dissolved in water, filtered with a 22 μm filter membrane, and freeze-dried under reduced pressure to obtain the fenbendazole methyl-β-cyclodextrin inclusion complex.

[0070] Example 3

[0071] A fenbendazole methyl-β-cyclodextrin inclusion compound, the preparation method of which comprises the following steps:

[0072] A 29.9 mg / mL fenbendazole formic acid solution and a 140 mg / mL methyl-β-cyclodextrin aqueous solution were mixed at a ratio of fenbendazole:methyl-β-cyclodextrin=1:2 (m / m), and stirred at 500 r / min for 3 hours at a temperature of 55°C. The resulting solution was stored in a refrigerator at 4°C for 8 hours, the solvent was removed by rotary evaporation, the residue was dissolved in water, filtered with a 22 μm filter membrane, and freeze-dried under reduced pressure to obtain the fenbendazole methyl-β-cyclodextrin inclusion complex.

[0073] Comparative Example

[0074] A fenbendazole methyl-β-cyclodextrin physical mixture, the preparation method of which comprises the following steps:

[0075] Fenbendazole and methyl-β-cyclodextrin are mixed (1:1, m / m), and stirred and ground to obtain the fenbendazole methyl-β-cyclodextrin physical mixture.

[0076] Test Example 1

[0077] Performance Characterization

[0078] 1. Differential Scanning Calorimetry Study

[0079] 5-10 mg of each of fenbendazole, methyl-β-cyclodextrin, fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1, and physical mixture prepared in the comparative example were subjected to differential scanning calorimetry analysis at N 2 Under the atmosphere, the air flow rate was 20 mL / min, one empty aluminum crucible was used as the reference tank, the other empty aluminum crucible was used as the sample tank, and the scanning speed was set to 10 °C / min.

[0080] 2. Scanning electron microscope image research

[0081] Fenbendazole, methyl-β-cyclodextrin, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 and the physical mixture prepared in the comparative example were observed using a ZEISS sigma300 scanning electron microscope. At a voltage of 5 kV, the samples were fixed on a copper plate with a conductive tape and sprayed with gold.

[0082] 3. Proton NMR research

[0083] Record the fenbendazole methyl-β-cyclodextrin inclusion complex and methyl-β-cyclodextrin prepared in Example 1 in D 2 Proton NMR spectroscopy (D 2 O-Bruker 400) and the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 were prepared in D 2 Roesy spectrum in O (Bruker 600).

[0084] 4. Determination of dissolution rate

[0085] The dissolution rate of fenbendazole, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 and the physical mixture prepared in the comparative example were tested. Each experiment was repeated 3 times, and the average of the 3 experimental results was taken to obtain a dissolution rate curve.

[0086] 5. Determination of fenbendazole content

[0087] Firstly, a fenbendazole HPLC standard curve was established.

[0088] HPLC analysis conditions: Agilent 1260 infinity high performance liquid chromatograph, C18-Ecosil column (250L×4.6mm), acetonitrile-water (70%:30%, v / v) as mobile phase, 25°C, injection volume of 10 μL, UV detector, flow rate of 1 mL / min, fenbendazole was analyzed.

[0089] Establishment of fenbendazole HPLC standard curve: HPLC analysis of fenbendazole ethanol solutions with concentrations of 0.01, 0.02, 0.04, 0.06, 0.08, and 0.1 mg / mL was performed using a 296 nm UV detector, and a fenbendazole HPLC standard curve was established based on the peak area and concentration.

[0090] An excess of fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 was dissolved in water (10 mL), and after ultrasonic oscillation at 37° C. for 2 h, the saturated aqueous solution was centrifuged and filtered, and HPLC analysis was performed. The content of fenbendazole in the inclusion complex was obtained based on the fenbendazole HPLC standard curve and regression equation.

[0091] 6. Determination of inclusion rate and inclusion yield

[0092] The inclusion rate of fenbendazole methyl-β-cyclodextrin inclusion complex and the yield of the inclusion complex are used as indicators for evaluating the inclusion effect. The inclusion rate and the inclusion yield of the inclusion complex can be calculated by the following formula:

[0093] Inclusion rate (%) = fenbendazole methyl-β-cyclodextrin inclusion complex (mg) / [fenbendazole (mg) + methyl-β-cyclodextrin (mg)] × 100%;

[0094] Inclusion yield (%) = [fenbendazole methyl-β-cyclodextrin inclusion complex (mg) / fenbendazole (mg)] × 100%.

[0095] 7. Determination of Cumulative Dissolution

[0096] According to the method specified in Appendix 160 of Part 1 of the 2015 edition of the Chinese Veterinary Pharmacopoeia, the in vitro dissolution was determined. Fenbendazole (100 mg), the fenbendazole methyl-β-cyclodextrin inclusion complex (containing 100 mg of the drug) prepared in Example 1, and the fenbendazole and methyl-β-cyclodextrin physical mixture (containing 100 mg of the drug) prepared in the comparative example were added to the reaction vessel, and then 900 mL of ultrapure water was added, ultrasonic degassed for 15 min, and stirred at a speed of 100 ± 3 r / min. At 37 ± 0.3 ° C. Samples (3 mL) were collected at 2, 5, 10, 15, 20, 30, 45 and 60 min, filtered with a 0.22 μm microporous syringe filter, and 3 mL of isothermal super-soluble medium (water) was added to the reaction vessel. The samples were analyzed by HPLC, and according to the HPLC peak area data, the fenbendazole HPLC standard curve and the regression equation, each test was repeated three times to obtain its cumulative dissolution.

[0097] 8. Determination of phase solubility

[0098] An excess of fenbendazole was added to 5, 10, 15, 20, 25, and 30 mmol / mL concentrations of β-cyclodextrin, methyl-β-cyclodextrin, HP-β-cyclodextrin, γ-cyclodextrin, and HP-γ-cyclodextrin aqueous solutions, respectively, stirred at room temperature for 48 h, filtered, and then analyzed by HPLC. Each test was repeated three times, and the phase solubility results were obtained based on the fenbendazole content in the solution.

[0099] Test results:

[0100] Figure 2 The differential scanning calorimetry scanning results of methyl-β-cyclodextrin, fenbendazole, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1, and the physical mixture prepared in the comparative example are shown.

[0101] The scanning results show that the endothermic event at 50-125°C in the curve of methyl-β-cyclodextrin is due to the loss of water from its cavity, and the endothermic events at 227°C and 237°C in the curve of fenbendazole are due to the melting effect. In the curve of the physical mixture of the two tautomers, the endothermic event in the range of 50-125°C is due to the dehydration of methyl-β-cyclodextrin. There are no endothermic events at 227°C and 237°C, while the endothermic event at 200°C indicates that there is an interaction between fenbendazole and methyl-β-cyclodextrin in its physical mixture. In the curve of the inclusion complex, the same thermal curve as that of methyl-β-cyclodextrin is presented, which may be due to the additional presence of methyl-β-cyclodextrin in the inclusion complex, and the peaks of fenbendazole at 227°C and 237°C disappear due to the formation of the inclusion complex.

[0102] Figure 3 The scanning electron microscope images of methyl-β-cyclodextrin, fenbendazole, fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 and physical mixture prepared in Comparative Example are shown;

[0103] in,

[0104] Figure 3 (a) is a scanning electron microscope image of methyl-β-cyclodextrin;

[0105] Figure 3 (b) is a scanning electron microscope image of fenbendazole;

[0106] Figure 3 (c) is a scanning electron microscope image of fenbendazole methyl-β-cyclodextrin inclusion complex;

[0107] Figure 3 (d) is the scanning electron microscope image of the physical mixture of fenbendazole and methyl-β-cyclodextrin.

[0108] Scanning electron microscopy images confirmed the formation of fenbendazole and methyl-β-cyclodextrin inclusion complex. Figure 3 As shown, fenbendazole is small flake crystals, methyl-β-cyclodextrin is spherical crystals, and in the morphology of the physical mixture, fenbendazole and methyl-β-cyclodextrin crystals are observed as a simple superposition of the following structures: fenbendazole and methyl-β-cyclodextrin, respectively, while the particle size and morphology of the inclusion complex are significantly different from those of the crystals of fenbendazole and methyl-β-cyclodextrin, indicating the formation of a new phase.

[0109] The changes in the morphology of solid particles observed in DSC and SEM confirm the formation of inclusion complexes. Nuclear magnetic resonance is the most effective method to study the spatial conformation of inclusion complexes.

[0110] Figure 4The nuclear magnetic resonance spectra of methyl-β-cyclodextrin, fenbendazole, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 and the physical mixture prepared in the comparative example are shown;

[0111] in,

[0112] Figure 4 (a) is methyl-β-cyclodextrin in D 2 Proton NMR spectrum in O;

[0113] Figure 4 (b) is the inclusion complex of fenbendazole methyl-β-cyclodextrin in D 2 Proton NMR spectrum in O;

[0114] Figure 4 (c) Fenbendazole methyl-β-cyclodextrin inclusion complex in D 2 Roesy spectrum in O.

[0115] according to Figure 4 It can be seen that fenbendazole methyl-β-cyclodextrin inclusion complex 2 The proton NMR peaks in O are: 7.70 (1H, s), 7.55 (1H, d), 7.25 (3H, m), 7.23 (2H, d), 7.00 (2H, d), 3.80 (3H, s); D 2 The Roesy spectrum in O showed the interaction between the protons of the phenyl group at 7.70 ppm, 7.55 ppm, and 7.23 ppm, the protons of the benzimidazole group at 7.25 ppm and 7.00 ppm, and the protons of methyl-β-cyclodextrin at 3.25 ppm to 3.85 ppm, confirming the formation of the inclusion complex. The ratio of the protons on fenbendazole to the protons on C-1 of methyl-β-cyclodextrin indicated that the inclusion complex contained one methyl-β-cyclodextrin molecule and one fenbendazole molecule.

[0116] Figure 5 The dissolution rates of fenbendazole, the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1, and the physical mixture prepared in the comparative example are shown. It can be seen that fenbendazole in the inclusion complex can be released by 75% within 15 minutes, which is 15 times higher than the release effect of fenbendazole alone or its physical mixture with methyl-β-cyclodextrin.

[0117] The inclusion rate of the fenbendazole methyl-β-cyclodextrin inclusion complex prepared in Example 1 was 29.2%, and the inclusion yield was 89.5%, which could increase the water solubility of fenbendazole from 0.3 μg / mL to 20.21 mg / mL.

[0118] Figure 6 The HPLC standard curve of fenbendazole established based on peak area and concentration is shown.

[0119] Figure 7 The solubility of fenbendazole in aqueous solutions of β-cyclodextrin at different concentrations is shown.

[0120] The complexation conditions of fenbendazole and methyl-β-cyclodextrin inclusion complex were determined by single factor and orthogonal experiments. A mixture of fenbendazole and methyl-β-cyclodextrin (1:1, m / m) in water was stirred at 50°C and 500r / min for 3h to obtain an inclusion complex with an inclusion rate of 29.2% and an inclusion yield of 89.5%. Among the inclusion complexes obtained under these conditions, the solubility of fenbendazole was the highest, reaching 20.21mg / mL, which was 60,000 times higher than that of fenbendazole alone (0.3μg / mL). The complex was used to confirm the formation of the inclusion complex and conduct in vitro and in vivo pharmacokinetic studies.

[0121] Test Example 2

[0122] 1. Pharmacokinetic studies

[0123] Twelve healthy adult dogs weighing 5±0.1kg, half male and half female, were randomly divided into two groups, namely, fenbendazole group and inclusion compound group (6 in each group), weighed and numbered, and raised in a new warm, clean and ventilated environment for 1 week. Fasted for 1 day before administration, fenbendazole or its inclusion compound was orally administered with water at a dose of 5 mg / kg, and 2 mL of blood was collected from the forearm vein at 0.00, 0.25, 0.5, 0.75, 1, 2, 4, 6, 10, 12, 24, and 48 hours after administration, and then immediately transferred to a heparinized test tube, centrifuged at 3500r / min for 10 minutes, and stored in a refrigerator at -20°C. During the blood collection period, the dogs were fed low-fat dog food and normal drinking water.

[0124] The plasma samples were then thawed to room temperature and washed with CH 2 Cl 2 (1 mL) was extracted, shaken for 4 min, and centrifuged at 13000 r / min for 10 min, repeated twice. The combined dichloromethane solution was placed in a 10 mL sterile centrifuge tube and blown with N at room temperature. 2 Evaporate, add 0.5 mL of methanol, shake for 4 min, centrifuge for 10 min, filter through a 0.22 μm filter at 13,000 r / min, and perform HPLC analysis.

[0125] The HPLC standard curve and sample analysis including plasma samples were completed on the same HPLC instrument and the same C-18 column in a short period of time to avoid systematic errors. The fenbendazole, oxfendazole, and fenbendazole sulfone standard solutions were checked by HPLC before and after HPLC analysis to confirm the stability of the HPLC analysis conditions, and no internal standard was used for calibration.

[0126] 2. Standard curves of fenbendazole, oxibendazole and fenbendazole sulfone in plasma

[0127] Concentration curves of fenbendazole, oxfendazole and fenbendazole sulfone in plasma were established: acetonitrile (0.5 mL) solutions of fenbendazole, oxfendazole and fenbendazole sulfone with concentrations of 10 μg / mL, 5 μg / mL, 1 μg / mL, 0.2 μg / mL, 0.1 μg / mL and 0.05 μg / mL were added to blank canine plasma (0.5 mL) in plastic centrifuge tubes. After vortexing and shaking, the mixture was extracted with dichloromethane and ethyl acetate and blown into N 2 , dissolved in methanol (1 mL), and analyzed by HPLC at 296 nm on a Shim-packVP-ODS C18 column (250 L×4.6 mm) to obtain the standard curves and regression equations of fenbendazole, oxabendazole and fenbendazole sulfone in plasma.

[0128] Test results:

[0129] Figure 8 Standard curves and regression equations for fenbendazole, oxibendazole, and fenbendazole sulfone in plasma are shown;

[0130] in,

[0131] Figure 8 (a) fenbendazole;

[0132] Figure 8 (b) is oxabendazole;

[0133] Figure 8 (c) is fenbendazole sulfone.

[0134] Fig. 9 The concentration-time curves of fenbendazole, oxfendazole and fenbendazole sulfone in the plasma of dogs taking fenbendazole or its methyl-β-cyclodextrin inclusion complex as determined by HPLC are shown;

[0135] in,

[0136] Fig. 9 (a) fenbendazole;

[0137] Fig. 9 (b) is oxabendazole;

[0138] Fig. 9 (c) is fenbendazole sulfone.

[0139] pass Fig. 9 It can be seen that the C of fenbendazole is max and T max The AUC increased from 4.41±1.27μg at 8.17h to 7.68±4.75μg in the inclusion group.0-48 The relative bioavailability of fenbendazole group increased from 60.68±19.91h·μg / mL to 83.65±51.63h·μg / mL in the inclusion complex group, and the relative bioavailability was 138%. max and T max The AUC increased from 1.38±0.69μg at 19.67±6.16h in the fenbendazole group to 4.13±1.97μg at 3.58±2.46h in the inclusion compound group. 0-48 The half-life T 1 / 2 The C of the secondary metabolite anthelmintic fenbendazole sulfone was extended from 10.25±5.46h to 15.25±11.88h. max and T max The AUC decreased from 4.11±3.03μg in the fenbendazole group (2.45±2.02h) to 3.65±2.55μg in the inclusion complex group (4.92±2.83h). 0-48 The relative bioavailability increased from fenbendazole group (11.93±8.68h·μg / mL) to inclusion compound group (20.24±13.97h·μg / mL), and the half-life T 1 / 2 Extended from 2.43±2.05h to 10.07±7.21h.

[0140] Fenbendazole is metabolized in the liver to oxfendazole, which is also an anthelmintic; oxfendazole is partially reduced to fenbendazole in the liver and rumen. Fenbendazole sulfone is a minor metabolite of fenbendazole in plasma and is also a benzimidazole anthelmintic.

[0141] The HPLC analysis conditions of dog plasma, fenbendazole, oxfendazole, and fenbendazole sulfone were established, in which dog plasma did not interfere with the detection of fenbendazole, oxfendazole, and fenbendazole sulfone. The standard curves and regression equations of fenbendazole, oxfendazole, and fenbendazole sulfone were established. The concentration of fenbendazole sulfone in plasma was established. In the range of 0.025μg / mL-5μg / mL, the HPLC peak area was linearly related to the concentration of fenbendazole, oxfendazole, and fenbendazole sulfone in the plasma solution, and the regression equation was obtained:

[0142] For fenbendazole, Y = 12.673X + 80.417 (R 2 =0.9954);

[0143] For oxfendazole, Y = 2768.6X + 25.592 (R 2 =0.996), and Y = 19.454X + 92.153 (R 2=0.9941);

[0144] in,

[0145] Y: HPLC peak area; X: concentration, LLOD (S / N≥3): 0.05 μg / mL, LLOQ: 0.15 μg / mL.

[0146] The concentrations of fenbendazole, oxfendazole and fenbendazole sulfone in plasma were determined by HPLC according to the standard equation and regression equation. The plasma concentration-time curve is shown in Fig. 9 The plasma pharmacokinetic curves (mean ± SD) were determined using a non-compartmental model and Phoenix WinNonlin 8 software, see Table 1.

[0147] Table 1 Pharmacokinetic parameters of fenbendazole, oxfendazole and fenbendazole sulfone in fenbendazole group and inclusion compound group (mean ± SD)

[0148]

[0149] Pharmacokinetic results showed that the AUC of fenbendazole, oxabendazole and fenbendazole sulfone was expanded. 0-48 and C max , prolonging the T of oxabendazole and fenbendazole sulfone 1 / 2 , through the use of inclusion complexes, the drug dosage can be reduced to achieve the same therapeutic effect. More importantly, since fenbendazole has anti-tumor activity, it is expected to promote further research on this effective compound.

[0150] In summary, the solubility of fenbendazole was increased to 20.21 mg / mL by reacting with methyl-β-cyclodextrin to form an inclusion complex, which is the best effect so far and is 60,000 times higher than the effect of fenbendazole alone. In addition, in the in vivo pharmacokinetic study, the release of fenbendazole was 75% within 15 minutes, and the bioavailability of fenbendazole and its main metabolic anthelmintic oxfendazole and the secondary metabolic anthelmintic oxfendazole were increased to 138%, 149% and 169%, respectively, so that it can achieve the same therapeutic effect at a lower dose, indicating that the inclusion complex can be used as a potential anticancer drug.

[0151] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.

[0152] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

[0153] References:

[0154] [1] Accioni, F., Caballero-Casero, N., García-Gómez, D., Rubio, S. Restricted access volatile supramolecular solvents for single step extraction / cleanup of benzimidazole anthelmintic drugs in milk prior to LC-MS / MS, J. Agric. Food Chem., 2019, 67(1):520-530.

[0155] [2]Mrkvová,Z.,Uldrijan,S.,Pombinho,A., P., Slaninová, I. Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmXoverexpressing tumor cells, Molecules. 2019; 24:2152.

[0156] [3]Duan, Q., Liu, Y., Rockwell, S. Fenbendazole as a potential anticancerdrug, Anticancer Res., 2013, 33: 355–362.

[0157] [4]Dogra, N., Kumar, A., Mukhopadhyay, T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways, Sci. Rep., 2018, 8: 11926.

[0158] [5]Tang,Y.,Liang,J.,Wu,A.,Chen,Y.,Zhao,P.,Lin,T.,et al.Co-delivery oftrichosanthin and albendazole by nano-self-assembly for overcoming tumormultidrug-resistance and metastasis,ACS Appl.Mater.Interfaces,2017,9:26648–26664.

[0159] [6]Chu,S.W.,Badar,S.,Morris,D.L.,Pourgholami,M.H.,Potent inhibitionof tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22human ovarian cancer cells by albendazole,Anticancer Res.,2009,29:3791–3796.

[0160] [7]Gu,J.l.,Zhao,H.,Liu,L.,Yang,G.,Preparation and characterization ofthe fenbendazol-β-cyclodextrin inclusion,Chemical Research and Application,2020,32(5):808-812.

[0161] [8]Jang-Ha,R.,James,D.,Sandra,E.K.,James,C.R.,Leonard,I.W.,A water-soluble fenbendazole formulation for treating pinworm infections inlaboratory animals,Drug Delivery Letters,2013,3(3):159-164.

[0162] [9]Effectiveness of anthelmintics:general recommendations VICHGL7.FDA;Rockville,USA:2001.Guidance for industry.Available via

[0163] http: / / fda.gov. / downloads / GFI-Anthelmintics-general-recommendations ;Fenbendazole(WHO Food Additives Series 29)Available via http: / / www.inchem.org / documents / jecfa / jecmono / v29je04.htm.

[0164]

[10] Rodrigues,L.N.C.,Tavares,A.C.M.,Ferreira,B.T.,Reis,A.K.C.A.,Katiki,L.M.,Inclusion complexes and self-assembled cyclodextrin aggregatesfor increasing the solubility of benzimidazoles.Braz.J.Pharm.Sci.,2019,55,1–11.

[0165]

[11] Artem,O.,Surov,N.A.,Vasilev,M.V.,Vener,O.D.,Parashchuk,A.V.,Churakov,O.V.,Magdysyuk,G.L.P.,Pharmaceutical salts of fenbendazole withorganic counterions:structural analysis and solubility performance,CrystalGrowth&Design,2021,21(8):4516-4530.DOI:10.1021 / acs.cgd.1c00413.

[0166]

[12] Ivan,A.A.,Salavat,S.K.,Konstantin,M.S.,Alexander,V.D.,Elizaveta,S.M.,Anastasiya,I.V.,Irina,M.O.,Nataliya,V.D.,Influence of mechanochemicaltechnology on anthelmintic efficacy of the supramolecular complex offenbendazole with polyvinylpyrrolidone,J.Adv.Vet.Anim.Res.,2019,6(1):133–141.

[0167]

[13] María,E.M.,Manuel,I.,Laura,C.,Alejandro,J.P.,Beatriz,M.,Ricardo,F.,Santiago,P.,Luis,I.A.,Laura,D.,Improving the in vitro dissolution rate andpharmacokinetic performance of fenbendazole in sheep using drug nanocrystals,Research in Veterinary Science,2022,142:110–116.

[0168]

[14] Esfahani,M.K.M.,Alavi,S.E.,Cabot,P.J.,Islam,N.,Izake,E.L.,PEGylated mesoporous silica nanoparticles(MCM-41):a promising carrier for thetargeteddelivery of fenbendazole into prostate cancer cells,Pharmaceutics,2021,13:1605.

[0169] https: / / doi.org / 10.3390 / pharmaceutics13101605.566.

[0170]

[15] Shin,Y.B.,Choi,J.Y.,Shin,D.H.,Lee,J.W.,Anticancer evaluation ofmethoxy poly(Ethylene Glycol)-b-Poly(Caprolactone)polymeric micellesencapsulating fenbendazole and rapamycin in ovarian cancer,InternationalJournal of Nanomedicine,2023,18:2209–2223.

[0171]

[16] Hickey,T.,Kreutzer,D.,Burgess,D.J.,Moussy,F.,Dexamethasone / PLGAmicrospheres for continuous delivery of an anti-inflammatory drug forimplantable medical devices.Biomaterials,2002;23:1649–1656.

[0172]

[17] Chang,C.S.,Ryu,J.Y.,Choi,J.K.,Cho,Y.J.,Choi,J.J.,Hwang,J.R.,Choi,J.Y.,Noh,J.J.,Lee,C,M.,Won,J,E.,Han,H.D.,Lee,J.W.,Anti-cancer effect offenbendazole-incorporated PLGA nanoparticles in ovarian cancer.J GynecolOncol.,2023,34(5):e58.

[0173]

[18] Bezerra,G.S.N.,de Lima,T.A.de M.,Colbert,D.M.,Geever,J.,Geever,L.,Formulation and evaluation of fenbendazole extended-release extrudesprocessed by hot-melt extrusion,Polymers,2022,14(19):4188.https: / / doi.org / 10.3390 / polym14194188.

[0174]

[19] Bezerra,G.S.N.,Moritz,V.F.,de Lima,T.A.de M.,Colbert,D.M.,Geever,J.,Geever,L.,Compatibility study between fenbendazole and polymericexcipients used in pharmaceutical dosage forms using thermal and non-thermalanalytical techniques,Analytica,2022,3(4):448-461.https: / / doi.org / 10.3390 / analytica3040031.

[0175]

[20] Bezerra,G.S.N.,De Lima,G.G.,Colbert,D.M.,Halligan,E.,Geever,J.,Geever,L.,Micro-injection moulding of PEO / PCL blend–based matrices forextended oral delivery of fenbendazole,Pharmaceutics,2023,15(3):900.https: / / doi.org / 10.3390 / pharmaceutics15030900.

[0176]

[21] Ding,Y.,Yu,B.,Zhang,J.,Ding,C.,Zhang,Z.,Xu,S.,Li,L.,Yu,H.Tilmicosin / γ-cyclodextrin complexation through supercritical carbondioxide assistance and its pharmacokinetic and antibacterial study,Eur.J.Pharm.Biopharma.,2022,181:104-112.

[0177]

[22] Ding,Y.,Yu,B.,Zhou,S.,Ding,C.,Zhang,Z.,Xu,S.,Xu,Z.Improvement ofsolubility and pharmacokinetic profile of hepatoprotector icariin throughcomplexation with HP-γ-cyclodextrin,Front.Pharmacol.,2023,14:11386862023.doi:10.3389 / fphar.2023.1138686.

[0178]

[23] Ding,Y.,Zhang,Z.,Ding,C.,Shufeng Xu Zhe Xu,The Use ofCyclodextrin inclusion complexes to increase the solubility andpharmacokinetic profile of albendazole,Molecules,2023,28(21):7295.

[0179]

[24] Ding,Y.,Cui,W.,Zhang,Z.,Ma,Y.,Ding,C.,Lin,Y.,Xu,Z.,Solubility andpharmacokinetic profile improvement of griseofulvin through supercriticalcarbon dioxide-assisted complexation with HP-γ-cyclodextrin,Molecules,2023,28(21):7360.

Claims

1. A fenbendazole methyl-β-cyclodextrin inclusion compound, characterized in that: The fenbendazole methyl-β-cyclodextrin inclusion compound comprises the following components: methyl-β-cyclodextrin and fenbendazole; The mass ratio of methyl-β-cyclodextrin to fenbendazole is (1-3):1; The preparation method of the fenbendazole methyl-β-cyclodextrin inclusion compound comprises the following steps: The methyl-β-cyclodextrin solution and the fenbendazole solution are mixed, stirred for reaction, and then the solvent is removed and the product is obtained after purification.

2. The fenbendazole methyl-β-cyclodextrin inclusion compound according to claim 1, characterized in that: The solvent of the fenbendazole solution is an organic acid.

3. The fenbendazole methyl-β-cyclodextrin inclusion compound according to claim 2, characterized in that: The organic acid is selected from one or more of formic acid and acetic acid.

4. The fenbendazole methyl-β-cyclodextrin inclusion compound according to claim 1, characterized in that: The temperature of the stirring reaction is: 20-60°C.

5. The fenbendazole methyl-β-cyclodextrin inclusion compound according to claim 1, characterized in that: The rotation speed of the stirring reaction is 300-550 r / min.

6. The fenbendazole methyl-β-cyclodextrin inclusion compound according to claim 1, characterized in that: The stirring reaction time is 2-5 h.

Citation Information

Patent Citations

  • Ivermectin controlled-release capsule and preparation method and application thereof

    CN107773554A

  • Methyl-beta-cyclodextrin and albendazole inclusion compound and preparation method thereof

    CN117357664A

  • Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition

    WO2015007759A1